NCT01605526View on ClinicalTrials.gov

A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Sarcoma
Interventions
DRUG

RO5045337

Multiple escalating oral doses, Days 1-5 (1-3) of each 28-day cycle, up to 6 cycles

DRUG

doxorubicin

60 mg/m2 (75 mg/m2, 50 mg/m2) iv on Day 1 of each 28-day cycle, up to 6 cycles

Trial Locations (9)

19111

Philadelphia

31059

Toulouse

33076

Bordeaux

69373

Lyon

90403

Santa Monica

94805

Villejuif

02115

Boston

07601

Hackensack

84132-0001

Salt Lake City

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01605526 - A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter